About Us
At Novo Genomics, we are committed to revolutionizing healthcare by harnessing the power of Genomics and Multi-omics—not only for humans through Clinical and Personal medicine but also for animals and plants through Agrigenomics.
We are a Saudi Biotech company focused on localizing and applying the technologies in genomics & multi-omics and leveraging data through advanced analytics and data mining to promote health and wellness in the region and beyond.
To be regionally trusted and globally recognized biotech leader in the field of genomics & multi-omics.
Why Novo Genomics?
Novo Genomics is a Saudi Biotechnology Company based in Riyadh, we believe that Genomics and Multi-omics will transform healthcare and wellness as we know it, not just for humans (Clinical & Personalized Medicine) but for animals and plants (Agri-genomics) as well. Our region has one of the highest prevalence (per capita) of genetic diseases worldwide. With a high-caliber core team, experienced advisors, and strategic investors, Novo Genomics has all the ingredients to be a serious player in the field of genomics / multi-omics in the region and beyond.
At Novo Genomics, we are honored to stand at the forefront of precision medicine in Saudi Arabia and the broader Middle East. Our journey is guided by a singular vision: to harness the power of genomics, data science, and next-generation biotechnology to transform healthcare delivery, improve patient outcomes, and contribute to a knowledge-based, innovation-driven economy.
As a Saudi-founded biotechnology company, we are deeply committed to developing solutions that are scientifically rigorous, regionally relevant, and clinically impactful. Through investments in localized research, strategic international collaborations, and cutting-edge technologies, we address critical gaps in diagnostics, preventive care, and population health—while upholding the highest standards of quality, ethics, and data integrity.
We take pride in supporting healthcare institutions, clinicians, and patients with a growing portfolio of genomic innovations that align with the Kingdom’s national priorities and the aspirations of Vision 2030. We also believe that sustained impact requires strategic collaboration—with government stakeholders, academic institutions, and the global scientific community.
At Novo Genomics, we are driven by purpose, powered by science, and inspired by the opportunity to shape the future of healthcare in the region and beyond. Thank you for your continued trust.
Warm regards,
Dr. Abdulelah Alhawsawi
Chief Executive Officer
Novo Genomics
